Stepping Up? Pharma’s Early COVID Pricing Decisions May Be Resolving Concerns

Pharmaceutical manufacturers so far appear to be making good on pledges to ensure that COVID-19 drugs and vaccines will be priced in a way that ensures access and affordability during the pandemic, according to a leading US payer participating in a series of recent colloquiums convened by the Institute for Clinical and Economic Review.

The discussions were part of an ICER initiative to develop a consensus on appropriate pricing for COVID-19 drugs and vaccines. The initiative also includes a white paper released by the group in July that laid out several possible pricing approaches